EUVIMEDEUVIMED entdecken
Crossref

Enhancing surgical outcomes: accurate identification and removal of prostate cancer with B7-H3-targeted NIR-II molecular imaging

Yaqi Tian, Hongliang Shen, Lingbing Li, Xiaohua Jia, Jin Liu, Zhenhua Hu, Liang Wang, Jie Tian iD

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-024-06714-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Yaqi Tian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong'an Road, Xicheng District, Beijing, 100050, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, B7 Antigens. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Hospitals Authority 10 Key Construction Projects Funding, Beijing Municipal Social Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: One of the main reasons for prostate cancer (PCa) recurrence is the difficulty in identifying and removing cancerous lesions during surgery. Accurately localizing and excising cancerous tissue remains a significant challenge. The second near-infrared window (NIR-II, 1000-1700 nm) fluorescence offers enhanced resolution, a high signal-to-noise ratio, and the potential for deeper tissue penetration. However, this technology is not currently employed for intraoperative imaging of PCa. This study aims to construct a new NIR-II probe targeting B7-H3 (AbB7-H3-800CW) for accurate intraoperative identification and resection of PCa. METHODS: Based on the differential expression of B7-H3 in PCa, we designed a novel imaging probe to accurately identify and guide the resection of preclinical PCa models and ex vivo human PCa tissues using NIR-II fluorescence imaging technology. RESULTS: Analyzing tissue samples from 60 clinical cases of PCa, along with benign prostatic hyperplasia and normal prostate tissue from 22 cases, we observed a significant difference in B7-H3 protein expression levels (P < 0.001). Subcutaneous and orthotopic mouse models of PCa were imaged using NIR-II fluorescence after AbB7-H3-800CW injection, showing promising results with successful tumor targeting and high-contrast images achieved within 24-48 h post-injection. The imaging also enabled the detection of occult PCa lesions approximately 1 mm in diameter. In addition, imaging analysis of human PCa and adjacent tissues using AbB7-H3-800CW incubation revealed that cancer tissues exhibited a significantly higher fluorescence intensity than adjacent tissues (P < 0.05), which was conducive to the evaluation of tumor resection margin in vitro. CONCLUSION: The findings revealed that B7-H3 was a compelling imaging target for PCa. The AbB7-H3-800CW molecular imaging probe is capable of accurately identifying PCa lesions and guiding their removal. This approach can potentially reduce the rate of surgical margins under NIR-II fluorescence guidance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsB7 AntigensMaleHumansMiceAnimalsMolecular ImagingCell Line, TumorInfrared RaysOptical ImagingSurgery, Computer-AssistedTreatment Outcome

Stichwörter der Autor:innen

FluorescenceMolecular imagingProstate cancerSecond near-infrared windowSurgery

Substanzen

B7 AntigensCD276 protein, human

Autor:innen und Institutionen

  • Department of Radiology, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong'an Road, Xicheng District, Beijing, 100050, China.
  • CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, No. 95 Zhongguancun East Road, Hai Dian District, Beijing, 100190, China.
  • Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Interventional Radiology Department, Chinese PLA General Hospital, Beijing, China.
  • CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, No. 95 Zhongguancun East Road, Hai Dian District, Beijing, 100190, China. zhenh…
  • National Key Laboratory of Kidney Diseases, Beijing, China. zhenhua.hu@ia.ac.cn.

ORCID-Profile: Jie Tian

Förderung

  • National Natural Science Foundation of China
  • Beijing Hospitals Authority 10 Key Construction Projects Funding
  • Beijing Municipal Social Science Foundation
  • CAS Youth Interdisciplinary Team
  • Technology's High Technology Research and Development
  • Technology’s High Technology Research and Development

Zitieren

APA

Tian, Y., Shen, H., Li, L., Jia, X., Liu, J., Hu, Z., Wang, L., & Tian, J. (2024). Enhancing surgical outcomes: accurate identification and removal of prostate cancer with B7-H3-targeted NIR-II molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06714-w

Vancouver

Tian Y, Shen H, Li L, Jia X, Liu J, Hu Z, et al. Enhancing surgical outcomes: accurate identification and removal of prostate cancer with B7-H3-targeted NIR-II molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06714-w

BibTeX
@article{Tian2024,
  author = {Tian, Yaqi and Shen, Hongliang and Li, Lingbing and Jia, Xiaohua and Liu, Jin and Hu, Zhenhua and Wang, Liang and Tian, Jie},
  title = {Enhancing surgical outcomes: accurate identification and removal of prostate cancer with B7-H3-targeted NIR-II molecular imaging},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-024-06714-w}
}
Kostenlos starten →